Clinical trials: Patient With Schizophrenia Spectrum Disorder
Schizophrenia, Schizoaffective Disorder
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT07105111
- Testing
- Valbenazine
- Where
- 19 sites in United States
- Volunteers
- 100 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia
Cognitive Adaptive Training for Improving Medication Adherence, Symptoms, and Function in People With Schizophrenia
This study will compare the effectiveness of three treatments in improving medication adherence, symptoms, and function in people with schizophrenia.
- Trial name
- NCT00455663
- Testing
- Cognitive Adaptation Training, Pharm-Cognitive Adaptation Training, Treatment as usual
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia, Schizoaffective Disorder
A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.
The purpose of this study is to document the long-term safety of 25, 50 or 75 mg long-acting injectable risperidone given via injection to the gluteal muscle every 2 weeks to patients with schizophrenia or schizoaffective…
- Trial name
- NCT00558298
- Testing
- risperidone
- Volunteers
- 811 people
- Sponsor
- Janssen, LP
Schizophrenia, Exercise
Comparison of the Effects of Aerobic Exercise and Computerized Cognitive Stimulation in Patients With Schizophrenia - A Randomized Controlled Trial
Schizophrenia is a chronic mental disorder characterized by the occurrence of both positive symptoms, such as hallucinations and delusions, and negative symptoms, such as apathy and withdrawal, repetition of cognitive skills and…
- Conditions
- Schizophrenia, Exercise, Computerized Cognitive Stimulation
- Trial name
- NCT06572657
- Testing
- cognitive stimulation, physical exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Dr. Lutfi Kirdar Kartal Training and Research Hospital
Schizoaffective Disorder, Schizophrenia
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
Background: Some illnesses, such as schizophrenia, have effects on brain cells called dopamine receptors, which are required for normal brain function.
- Trial name
- NCT00942981
- Testing
- PET
- Where
- United States
- Volunteers
- 283 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning.
- Trial name
- NCT04860830
- Testing
- Iclepertin
- Where
- 110 sites in United States, Argentina and 16 more
- Volunteers
- 609 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia Disorder
A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398
This is an open label study in 2 cohorts of healthy volunteers and 1 cohort of patients with Schizophrenia, designed to evaluate the Dopamine D2 and D3 Receptor Occupancy by SIPI6398 at various doses and timepoints.
- Trial name
- NCT07626034
- Testing
- SIPI6398 Tablets
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongze Therapeutics Co., Ltd.
Motivational Interviewing, Schizophrenia Spectrum Disorder
Effects of Adherence Therapy on Medication Adherence in Patients With Schizophrenia Spectrum Disorder
This study will explore the effect of Adherence Therapy(AT) on medication adherence in patients with schizophrenia spectrum disorder.
- Conditions
- Motivational Interviewing, Schizophrenia Spectrum Disorder, Medication Adherence
- Trial name
- NCT04022577
- Testing
- Adherence Therapy, control group
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Yang Ming Chiao Tung University
Autism Spectrum Disorders, Schizophrenia
Visual Exploration and Attention: Studies in Patients With Schizophrenia and Autism Spectrum Disorders
The aim of the protocol is to better understand the impairments in visual processing, as such impairments may induce social interaction difficulties in subjects with autism spectrum disorders (adults and children) and…
- Trial name
- NCT00914030
- Testing
- Neuropsychological evaluation
- Where
- 5 sites in France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Schizophrenia
PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations
The primary goal of the present study is to evaluate the utility of mGluR5 binding as measured by PET as biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation.
- Trial name
- NCT02983058
- Testing
- PET/SPECT Scan, MRI Scan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jeffrey A. Lieberman, MD
Schizophrenia
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy of paliperidone palmitate 3 month formulation (PP3M) compared with placebo in delay of the time to first occurrence of relapse of the symptoms of schizophrenia.
- Trial name
- NCT01529515
- Testing
- PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq.
- Where
- 53 sites in United States, Colombia and 6 more
- Volunteers
- 509 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
Digoxin Drug-Drug Interaction With Lurasidone HCl
The objective of this study is to evaluate the pharmacokinetic profile of digoxin when administered alone and when administered with repeated dose of lurasidone 120mg.
- Trial name
- NCT01082289
- Testing
- Lurasidone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Cognitive Effect on Schizophrenic Patients
Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia
This is a randomized, double-blind, active-controlled, 6 month study designed to evaluate the cognitive effects of treatment with CYP-1020 compared to risperidone.
- Trial name
- CLARITY (NCT01363349)
- Testing
- CYP-1020, Risperidone
- Where
- 39 sites in India, Moldova and 1 more
- Volunteers
- 269 people
- Sponsor
- BioLineRx, Ltd.
Schizophrenia
Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia
Antipsychotic alone is limit to improve the overall outcome of schizophrenia and has a high discontinue rate.To solve these problems, we provide practical and available psychosocial intervention.
- Trial name
- ACPIOS (NCT00654576)
- Testing
- Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole, psychosocial intervention
- Where
- China
- Volunteers
- 1,400 people
- Sponsor
- Central South University
Schizophrenia
Efficacy of Lu 31-130 in Patients With Schizophrenia
The main purpose with the study is to evaluate the efficacy and safety of Lu 31-130 in patients suffering from schizophrenia compared to placebo.
- Trial name
- NCT00768326
- Testing
- Zicronapine
- Where
- Germany
- Volunteers
- 280 people
- Sponsor
- H. Lundbeck A/S
Depression, Schizophrenia
Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
This is a research study comparing the safety and efficacy of two active study medications
- Conditions
- Depression, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00034801
- Testing
- olanzapine, ziprasidone
- Where
- 30 sites in United States
- Volunteers
- 378 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
A review of the amount of drug in your blood over time.
- Trial name
- NCT02186769
- Testing
- Risperdal® Consta®, LY03004
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenic Disorders
Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
The trial is designed to assess the long term subjective well-being in schizophrenic outpatients treated with quetiapine XR (extended release) or oral risperidone at flexible dose in a naturalistic setting over a period of one…
- Trial name
- RECOVER (NCT00600756)
- Testing
- Quetiapine XR, Risperidone
- Where
- 116 sites in Belgium, Brazil and 12 more
- Volunteers
- 798 people
- Sponsor
- AstraZeneca
Schizophrenia
IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)
To evaluate efficacy and tolerability of Ziprasidone IM and oral in agitated patients with acute exacerbation of schizophrenia
- Trial name
- NCT00136994
- Testing
- Ziprasidone
- Where
- 34 sites in Italy
- Volunteers
- 160 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Memantine add-on for Cognitive and Negative Symptoms of Schizophrenia
The specific aim of this project is to test if memantine add-on therapy will be helpful for patients with first episode schizophrenia who present with or without cognitive impairments and negative symptoms, to examine the…
- Trial name
- NCT02001103
- Testing
- Memantine
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.